Trends in Molecular Medicine
ReviewRecent advances in insulin gene therapy for type 1 diabetes
Section snippets
Insulin gene transfer systems
The transfer of defined genetic material to specific target cells is an essential component of gene therapy. It can be accomplished using nonviral or viral vectors.
Glucose-responsive insulin production
Pancreatic β cells contain unique features that allow the regulation of insulin synthesis and secretion in response to physiological glucose concentrations. It is not easy to reconstruct this regulated system outside of the pancreatic β cells, as several cellular structures and proteins are required for the secretion of insulin in response to changes in extracellular glucose concentrations, including cis- and trans-activating factors, glucose transporter (Glut) 2, glucokinase (GK) and
Production of biologically active insulin
Insulin is a polypeptide hormone that consists of two polypeptide chains, A and B, linked by two interchain and one intrachain disulfide bond. Insulin is synthesized as a single-chain precursor, preproinsulin. Cleavage of a 24-residue N-terminal ‘signal sequence’ from preproinsulin yields proinsulin, an 81-residue polypeptide consisting of A- and B-chains separated by a connecting (C)-peptide. Proinsulin is packaged into storage secretory granules where it undergoes folding and disulfide bond
Target cell for insulin gene expression
Pancreatic β cells in type 1 diabetic patients are the target of autoimmune attack, requiring that subjects undergoing islet cell transplantation be maintained on immunosuppressant drugs, which have adverse side-effects in some cases. A distinct advantage of insulin gene therapy is that non-β cells that are genetically engineered to produce insulin should not be recognized by these autoimmune responses [48]. However, such somatic insulin gene therapy is hampered by the complexity of insulin
Concluding remarks
Insulin gene therapy has been investigated as a possible method for the permanent treatment of type 1 diabetes (Fig. 4). With advances in molecular biological and recombinant DNA techniques, and our increased understanding of the biochemical mechanisms of glucose-regulated insulin secretion from β cells, significant progress has been made. Although glucose-responsive expression of transgenic insulin has been achieved, none of the insulin gene therapy trials to date was able to mimic normal β
Acknowledgements
We thank A.L. Kyle for editorial assistance. J-W.Y. is a Heritage Medical Scientist Awardee of the Alberta Heritage Foundation for Medical Research and holds a Canada Research Chair in Diabetes. This work was supported by the Canadian Institutes of Health Research and the National Institutes of Health.
References (62)
- et al.
Insulin-dependent diabetes mellitus
- et al.
Towards gene therapy of diabetes mellitus
Mol. Med. Today
(1999) Toward engineering skeletal muscle to release peptide hormone from the human pre-proinsulin gene
Transplant. Proc.
(1998)- et al.
Development of lentiviral vectors for gene therapy for human diseases
Blood
(2000) - et al.
Expanded-capacity adenoviral vectors – the helper-dependent vectors
Mol. Med. Today
(1999) - et al.
Adeno-associated virus vectors and hematology
Blood
(1999) Adeno-associated virus: integration at a specific chromosomal locus
Curr. Opin. Genet. Dev.
(1993)Respective roles of glucose, fructose, and insulin in the regulation of the liver-specific pyruvate kinase gene promoter
J. Biol. Chem.
(1994)Two CACGTG motifs with proper spacing dictate the carbohydrate regulation of hepatic gene transcription
J. Biol. Chem.
(1995)Exploration of a liver-specific, glucose/insulin-responsive promoter in transgenic mice
J. Biol. Chem.
(1993)
Definition of the carbohydrate response element of the rat S14 gene. Evidence for a common factor required for carbohydrate regulation of hepatic genes
J. Biol. Chem.
Deletion of a highly conserved tetrapeptide sequence of the proinsulin connecting peptide (C-peptide) inhibits proinsulin to insulin conversion by transfected pituitary corticotroph (AtT20) cells
J. Biol. Chem.
β-granule transport and exocytosis
Semin. Cell Dev. Biol.
Expression of the human insulin gene and cDNA in a heterologous mammalian system
J. Biol. Chem.
Transfection of AtT-20ins cells with GLUT-2, but not GLUT-1, confers glucose-stimulated insulin secretion. Relationship to glucose metabolism
J. Biol. Chem.
Islet cell transplantation
Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
New Engl. J. Med.
Pancreatic transplantation: a review
Int. Surg.
Lessons learned from more than 1000 pancreas transplants at a single institution
Ann. Surg.
Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells
Nat. Med.
In vitro cultivation of human islets from expanded ductal tissue
Proc. Natl. Acad. Sci. U. S. A.
Cloning and sequencing of the pancreatic islet neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in hamsters
J. Clin. Invest.
Nonviral vectors in the new millennium: delivery barriers in gene transfer
Hum. Gene Ther.
In vivo expression of rat insulin after intravenous administration of the liposome-entrapped gene for rat insulin I
Proc. Natl. Acad. Sci. U. S. A.
Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue
Nature
Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system
Nat. Genet.
Nonviral strategies for gene therapy
Sci. Am.
Insulin delivery with plasmid DNA
Hum. Gene Ther.
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Nat. Med.
Viral vectors for gene transfer: a review of their use in the treatment of human diseases
Drugs
Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus
J. Virol.
Cited by (56)
Gene therapy and type 1 diabetes mellitus
2018, Biomedicine and PharmacotherapyCitation Excerpt :Leptin in physiological concentrations seem to inhibit secretion of insulin only when the islets are maximally stimulated with high glucose concentrations [27]. Hyperleptinemia has been demonstrated to induce pathophysiological onset of T1DM and T2DM [26]. Euglycemia was achieved and sustained for the 7 weeks duration of experiment in severely insulinopenic Akita mice that suffers from a dominant mutation in Ins 2 gene after administration of leptin through recombinant adeno-associated virus vector (rAAV-Lep) [26].
Nanostructures for oral delivery of therapeutic nucleic acids
2017, Nanostructures for Oral MedicineMultivariate calibration of NIR spectroscopic sensors for continuous glucose monitoring
2015, TrAC - Trends in Analytical ChemistryCitation Excerpt :The Diabetes Care and Complications Trial (DCCT) demonstrated that tight glycemic control delayed the onset of many of those complications and that tight glycemic control was accomplished by frequent monitoring of blood glucose coupled with insulin therapy [7]. So far, the most successful way to control blood-glucose levels and delay onset of diabetic complications is through insulin therapy [8]. Proper use of insulin can prevent death from ketoacidosis in people with Type 1 or Type 2 diabetes and reduce complications due to chronic hyperglycemia in people with Type 2 diabetes [9].
Glucose-regulated insulin production in the liver improves glycemic control in type 1 diabetic mice
2015, Molecular MetabolismRegulation of insulin biosynthesis in non-beta cells by a heat shock promoter
2013, Journal of Bioscience and Bioengineering